Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 DBMR VENDOR SHARE ANALYSIS
2.1 MARKET APPLICATION COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES ANALYSIS
4.1.1 THREAT OF NEW ENTRANTS
4.1.2 BARGAINING POWER OF SUPPLIERS
4.1.3 BARGAINING POWER OF BUYERS
4.1.4 THREAT OF SUBSTITUTE PRODUCTS
4.1.5 INDUSTRY RIVALRY
4.2 PESTEL ANALYSIS
4.2.1 POLITICAL FACTORS
4.2.2 ECONOMIC FACTORS
4.2.3 SOCIAL FACTORS
4.2.4 TECHNOLOGICAL FACTORS
4.2.5 ENVIRONMENTAL FACTORS
4.2.6 LEGAL FACTORS
4.3 COMPANY EVALUATION QUADRANT
4.4 PATENT ANALYSIS
4.4.1 PATENT QUALITY AND STRENGTH
4.4.2 PATENT FAMILIES
4.4.3 LICENSING AND COLLABORATIONS
4.4.4 COMPETITIVE LANDSCAPE
4.4.5 IP STRATEGY AND MANAGEMENT
4.5 VALUE CHAIN ANALYSIS
4.5.1 CLINICAL TESTING & DIAGNOSTIC SERVICES
4.5.2 REAGENTS & CONSUMABLES
4.5.3 SAMPLE COLLECTION & PRE-ANALYTICS
4.5.4 R&D / BIOMARKER DISCOVERY & COMPANION DIAGNOSTICS
4.5.5 DISTRIBUTION, SALES & CLINICAL ADOPTION PROGRAMS
4.6 COST ANALYSIS BREAKDOWN
4.6.1 SAMPLE COLLECTION AND LOGISTICS
4.6.2 REAGENTS AND CONSUMABLES
4.6.3 SEQUENCING AND TECHNOLOGY INFRASTRUCTURE
4.6.4 LABOR, EXPERTISE, AND COMPLIANCE
4.6.5 RESEARCH, DEVELOPMENT, AND EVIDENCE GENERATION
4.6.6 SALES, MARKETING, AND EDUCATION
4.7 HEALTHCARE ECONOMY
4.7.1 HEALTHCARE EXPENDITURE
4.7.2 CAPITAL EXPENDITURE
4.7.3 CAPEX TRENDS
4.7.4 CAPEX ALLOCATION
4.7.5 FUNDING SOURCES
4.7.6 INDUSTRY BENCHMARKS
4.7.7 GDP RATIO IN OVERALL GDP
4.7.8 HEALTHCARE SYSTEM STRUCTURE
4.7.9 GOVERNMENT POLICIES
4.7.10 ECONOMIC DEVELOPMENT
4.8 INDUSTRY INSIGHTS FOR U.S. LIQUID BIOPSY MARKET
4.8.1 MICRO AND MACRO ECONOMIC FACTORS
4.8.2 PENETRATION AND GROWTH PROSPECT MAPPING
4.8.3 KEY PRICING STRATEGIES
4.8.4 INTERVIEWS WITH SPECIALISTS
4.8.5 ANALYSIS AND RECOMMENDATION
4.9 INNOVATION TRACKER AND STRATEGIC ANALYSIS
4.9.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
4.9.1.1 JOINT VENTURES
4.9.1.2 MERGERS AND ACQUISITIONS
4.9.1.3 LICENSING AND PARTNERSHIP
4.9.1.4 TECHNOLOGY COLLABORATIONS
4.9.1.5 STRATEGIC DIVESTMENTS
4.9.2 NUMBER OF PRODUCTS IN DEVELOPMENT
4.9.3 STAGE OF DEVELOPMENT
4.9.4 TIMELINES AND MILESTONES
4.9.5 INNOVATION STRATEGIES AND METHODOLOGIES
4.9.6 RISK ASSESSMENT AND MITIGATION
4.9.7 FUTURE OUTLOOK
4.1 OPPORTUNITY MAP ANALYSIS
4.10.1 EARLY CANCER DETECTION
4.10.2 MINIMAL RESIDUAL DISEASE (MRD) MONITORING
4.10.3 COMPANION DIAGNOSTICS
4.10.4 MULTI-CANCER APPLICATIONS
4.10.5 TECHNOLOGICAL INNOVATIONS & AI INTEGRATION
4.11 REIMBURSEMENT FRAMEWORK
4.11.1 KEY AUTHORITIES & PAYERS
4.11.2 COVERAGE PATHWAYS
4.11.3 EVIDENCE REQUIREMENTS
4.11.4 REIMBURSEMENT CHALLENGES
4.11.5 STRATEGIC APPROACHES
4.12 SUPPLY CHAIN ECOSYSTEM
4.12.1 PROMINENT COMPANIES
4.12.2 SMALL & MEDIUM-SIZED COMPANIES
4.12.3 END USERS
4.13 TECHNONLOGY ROADMAP
4.13.1 PHASE 1: FOUNDATIONAL PLATFORM MATURATION
4.13.2 PHASE 2: EXPANSION INTO MRD AND SURVEILLANCE
4.13.3 PHASE 3: MULTI-CANCER EARLY DETECTION (MCED)
4.13.4 PHASE 4: DIGITAL INTEGRATION & PERSONALIZED MONITORING
4.13.5 PHASE 5: BEYOND ONCOLOGY – MULTI-DISEASE EXPANSION
5 TARIFFS AND THEIR IMPACT ON MARKET
5.1 CURRENT TARIFF RATES IN TOP-5 COUNTRY MARKETS
5.2 OUTLOOK: LOCAL PRODUCTION VS IMPORT RELIANCE
5.3 VENDOR SELECTION CRITERIA DYNAMICS
5.4 IMPACT ON SUPPLY CHAIN
5.4.1 RAW MATERIAL PROCUREMENT
5.4.2 MANUFACTURING AND PRODUCTION
5.4.3 LOGISTICS AND DISTRIBUTION
5.4.4 PRICE PITCHING AND POSITION OF MARKET
5.5 INDUSTRY PARTICIPANTS: PROACTIVE MOVES
5.5.1 SUPPLY CHAIN OPTIMIZATION
5.5.2 JOINT VENTURE ESTABLISHMENTS
5.6 IMPACT ON PRICES
5.7 REGULATORY INCLINATION
5.7.1 GEOPOLITICAL SITUATION
5.7.2 TRADE PARTNERSHIPS BETWEEN COUNTRIES
5.7.2.1 FREE TRADE AGREEMENTS
5.7.2.2 ALLIANCE ESTABLISHMENTS
5.7.3 STATUS ACCREDITATION (INCLUDING MFN)
5.7.4 DOMESTIC COURSE OF CORRECTION
5.7.4.1 INCENTIVE SCHEMES TO BOOST PRODUCTION OUTPUTS
5.7.4.2 ESTABLISHMENT OF SPECIAL ECONOMIC ZONES / INDUSTRIAL PARKS
6 REGULATORY COMPLIANCE
6.1.1 REGULATORY AUTHORITIES
6.1.2 REGULATORY CLASSIFICATIONS
6.1.3 REGULATORY SUBMISSIONS
6.1.4 INTERNATIONAL HARMONIZATION
6.1.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
6.1.6 REGULATORY CHALLENGES AND STRATEGIES
7 MARKET OVERVIEW
7.1 DRIVER
7.1.1 RISING CANCER INCIDENCE GLOBALLY
7.1.2 ADVANCEMENTS IN NGS AND CTDNA ANALYSIS
7.1.3 INCREASING DEMAND FOR EARLY AND ACCURATE CANCER DIAGNOSIS
7.1.4 GROWING PREFERENCE FOR NON-INVASIVE, REPEATABLE TESTING
7.2 RESTRAINTS
7.2.1 HIGH COST OF ADVANCED LIQUID BIOPSY TECHNOLOGIES
7.2.2 LIMITED CLINICAL VALIDATION FOR CERTAIN CANCER TYPES
7.3 OPPORTUNITY
7.3.1 GROWTH IN EMERGING MARKETS FROM HEALTH INFRASTRUCTURE AND INTEGRATION WITH AI
7.3.2 R&D PARTNERSHIPS, MERGERS & ACQUISITIONS
7.3.3 EXPANSION INTO NON-CANCER APPLICATIONS
7.4 CHALLENGES
7.4.1 LIMITED AWARENESS AND COMPETITION FROM NEW DIAGNOSTIC MODALITIES
7.4.2 VARIABILITY IN TEST SENSITIVITY AND STANDARDIZATION
8 U.S. LIQUID BIOPSY MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 CONSUMABLES & ACCESSORIES
8.3 INSTRUMENTS
8.4 SERVICES & SOFTWARE
9 U.S. LIQUID BIOPSY MARKET, BY BIOMARKER TYPE
9.1 OVERVIEW
9.2 CIRCULATING TUMOR CELLS (CTCS)
9.3 CIRCULATING CELL-FREE DNA (CFDNA)
9.4 CELL-FREE RNA
9.5 EXOSOMES
9.6 EXTRACELLULAR VESICLES
9.7 OTHERS
10 U.S. LIQUID BIOPSY MARKET, BY SAMPLE TYPE
10.1 OVERVIEW
10.2 BLOOD SAMPLE-BASED
10.3 URINE SAMPLE-BASED
10.4 SALIVA FLUID
10.5 CEREBROSPINAL FLUID (CSF)
10.6 PLEURAL FLUID
10.7 TISSUE FLUID
10.8 OTHERS
11 U.S. LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE
11.1 OVERVIEW
11.2 MOLECULAR
11.3 PROTEOMIC
11.4 HISTOLOGY/IMAGING
12 U.S. LIQUID BIOPSY MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 CANCER APPLICATIONS
12.3 NON-CANCER APPLICATIONS
13 U.S. LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION
13.1 OVERVIEW
13.2 ROUTINE SCREENING
13.3 THERAPY SELECTION
13.4 TREATMENT MONITORING
13.5 RECURRENCE MONITORING
13.6 PATIENT WORK-UP
13.7 OTHERS
14 U.S. LIQUID BIOPSY MARKET, BY TECHNOLOGY
14.1 OVERVIEW
14.2 NEXT-GENERATION SEQUENCING (NGS)
14.3 POLYMERASE CHAIN REACTION (PCR)
14.4 IMMUNOASSAYS & MASS SPECTROMETRY
14.5 MICROFLUIDICS-BASED
14.6 NANOTECHNOLOGY
14.7 MICROARRAYS
15 U.S. LIQUID BIOPSY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 REFERENCE LABORATORIES
15.4 DIAGNOSTICS CENTERS
15.5 RESEARCH CENTRES AND ACADEMIC INSTITUTES
15.6 CLINICS
15.7 OTHERS
16 U.S. LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 THIRD PARTY DISTRIBUTOR
16.4 OTHERS
16.5 U.S. LIQUID BIOPSY MARKET, COMPANY LANDSCAPE
16.6 COMPANY SHARE ANALYSIS: U.S.
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 GUARDANT HEALTH
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENT
18.2 F. HOFFMANN-LA ROCHE LTD
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 PRODUCT PORTFOLIO
18.2.4 RECENT DEVELOPMENT
18.3 EXACT SCIENCES CORPORATION.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT DEVELOPMENT
18.4 QUEST DIAGNOSTICS INC
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENTS/NEWS
18.5 NATERA, INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENTS/NEWS
18.6 ANGLE PLC
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 CARIS LIFE SCIENCES
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENTS/NEWS
18.8 EUROFINS SCIENTIFIC
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS/NEWS
18.9 LABCORP
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS/NEWS
18.1 MDXHEALTH
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 PRODUCT PORTFOLIO
18.10.4 RECENT DEVELOPMENTS/NEWS
18.11 NEOGENOMICS LABORATORIES.
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENT
18.12 ONCOCYTE CORP.
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS/NEWS
18.13 PREDICINE
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENTS/NEWS
18.14 TEMPUS
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS/NEWS
18.15 VERACYTE, INC
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENTS/NEWS
19 QUESTIONNAIRE
20 RELATED REPORTS
List of Table
TABLE 1 U.S. LIQUID BIOPSY MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 2 U.S. CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 3 U.S. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 4 U.S. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 5 U.S. ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 6 U.S. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 7 U.S. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY MODALITY, 2018-2032 (USD THOUSAND)
TABLE 8 U.S. BENCHTOP IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 U.S. STANDALONE IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 10 U.S. MODULAR SYSTEMS IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 U.S. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY AUTOMATION, 2018-2032 (USD THOUSAND)
TABLE 12 U.S. AUTOMATIC IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 13 U.S. MANUAL / SEMI-AUTOMATIC IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 U.S. SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 15 U.S. LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 U.S. EXTRACELLULAR VESICLES IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 17 U.S. LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2018-2032 (USD THOUSAND)
TABLE 18 U.S. LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2018-2032 (USD THOUSAND)
TABLE 19 U.S. MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2018-2032 (USD THOUSAND)
TABLE 20 U.S. PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 U.S. LIQUID BIOPSY MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 22 U.S. CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 23 U.S. BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 24 U.S. NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 25 U.S. LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 26 U.S. TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 27 U.S. LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 28 U.S. NEXT-GENERATION SEQUENCING (NGS) IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 29 U.S. POLYMERASE CHAIN REACTION (PCR)-BASED IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 U.S. IMMUNOASSAYS & MASS SPECTROMETRY IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 31 U.S. MICROFLUIDICS-BASED IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 32 U.S. NANOTECHNOLOGY IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 33 U.S. NANOPARTICLE-BASED ASSAYS IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 U.S. MICROARRAYS IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 U.S. DNA MICROARRAYS IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 36 U.S. RNA MICROARRAYS IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 U.S. PROTEIN MICROARRAYS IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 38 U.S. EPIGENETIC MICROARRAYS IN LIQUID BIOPSY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 39 U.S. LIQUID BIOPSY MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 40 U.S. LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 U.S. LIQUID BIOPSY MARKET
FIGURE 2 U.S. LIQUID BIOPSY MARKET: DATA TRIANGULATION
FIGURE 3 U.S. LIQUID BIOPSY MARKET: DROC ANALYSIS
FIGURE 4 U.S. LIQUID BIOPSY MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 U.S. LIQUID BIOPSY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 U.S. LIQUID BIOPSY MARKET: MULTIVARIATE MODELLING
FIGURE 7 U.S. LIQUID BIOPSY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 U.S. LIQUID BIOPSY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 U.S. LIQUID BIOPSY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 END USER COVERAGE GRID
FIGURE 11 U.S. LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 INCREASING ADOPTION OF MINIMALLY INVASIVE DIAGNOSTIC TECHNIQUES IS EXPECTED TO DRIVE THE U.S. LIQUID BIOPSY MARKET IN THE FORECAST PERIOD (2025-2032)
FIGURE 15 THE CONSUMABLES & ACCESSORIES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. LIQUID BIOPSY MARKET IN 2025 AND 2032
FIGURE 16 PORTER’S FIVE FORCES ANALYSIS
FIGURE 17 PESTEL ANALYSIS
FIGURE 18 COMPANY EVALUATION QUADRANT
FIGURE 19 TOTAL PATENTS IN THE U.S. LIQUID BIOPSY MARKET
FIGURE 20 VALUE CHAIN OF U.S. LIQUID BIOPSY MARKET
FIGURE 21 U.S. LIQUID BIOPSY MARKET: BY PRODUCT, 2024
FIGURE 22 U.S. LIQUID BIOPSY MARKET: BY PRODUCT, 2025 TO 2032 (USD THOUSAND)
FIGURE 23 U.S. LIQUID BIOPSY MARKET: BY PRODUCT, CAGR (2025- 2032)
FIGURE 24 U.S. LIQUID BIOPSY MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 25 U.S. LIQUID BIOPSY MARKET: BY BIOMARKER TYPE, 2024
FIGURE 26 U.S. LIQUID BIOPSY MARKET: BY BIOMARKER TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 27 U.S. LIQUID BIOPSY MARKET: BY BIOMARKER TYPE, CAGR (2025- 2032)
FIGURE 28 U.S. LIQUID BIOPSY MARKET: BY BIOMARKER TYPE, LIFELINE CURVE
FIGURE 29 U.S. LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2024
FIGURE 30 U.S. LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 31 U.S. LIQUID BIOPSY MARKET: BY SAMPLE TYPE, CAGR (2025- 2032)
FIGURE 32 U.S. LIQUID BIOPSY MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 33 U.S. LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2024
FIGURE 34 U.S. LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 35 U.S. LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, CAGR (2025- 2032)
FIGURE 36 U.S. LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, LIFELINE CURVE
FIGURE 37 U.S. LIQUID BIOPSY MARKET: BY APPLICATION, 2024
FIGURE 38 U.S. LIQUID BIOPSY MARKET: BY APPLICATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 39 U.S. LIQUID BIOPSY MARKET: BY APPLICATION, CAGR (2025- 2032)
FIGURE 40 U.S. LIQUID BIOPSY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 41 U.S. LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2024
FIGURE 42 U.S. LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 43 U.S. LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, CAGR (2025- 2032)
FIGURE 44 U.S. LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, LIFELINE CURVE
FIGURE 45 U.S. LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2024
FIGURE 46 U.S. LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2025 TO 2032 (USD THOUSAND)
FIGURE 47 U.S. LIQUID BIOPSY MARKET: BY TECHNOLOGY, CAGR (2025- 2032)
FIGURE 48 U.S. LIQUID BIOPSY MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 49 U.S. LIQUID BIOPSY MARKET: BY END USER, 2024
FIGURE 50 U.S. LIQUID BIOPSY MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)
FIGURE 51 U.S. LIQUID BIOPSY MARKET: BY END USER, CAGR (2025- 2032)
FIGURE 52 U.S. LIQUID BIOPSY MARKET: BY END USER, LIFELINE CURVE
FIGURE 53 U.S. LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 54 U.S. LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)
FIGURE 55 U.S. LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025- 2032)
FIGURE 56 U.S. LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 57 U.S. LIQUID BIOPSY MARKET: COMPANY SHARE 2024 (%)
